The Experts below are selected from a list of 478917 Experts worldwide ranked by ideXlab platform
Yang Cao - One of the best experts on this subject based on the ideXlab platform.
-
dose response Relationship between dietary magnesium intake and cardiovascular mortality a systematic review and dose based meta regression analysis of prospective studies
Journal of Trace Elements in Medicine and Biology, 2016Co-Authors: Xin Fang, Jan Aaseth, Chun Liang, Scott Montgomery, Yang Cao, Katja FallAbstract:Abstract Background Although epidemiology studies have reported the Relationship, including a Dose-Response Relationship, between dietary magnesium intake and risk of cardiovascular disease (CVD), the risk for CVD mortality is inconclusive and the evidence for a Dose-Response Relationship has not been summarized. Objective We conducted a systematic review and meta-analysis of prospective studies to summarize the evidence regarding the association of dietary magnesium intake with risk of CVD mortality and describe their Dose-Response Relationship. Design We identified relevant studies by searching major scientific literature databases and grey literature resources from their inception to August 2015, and reviewed references lists of retrieved articles. We included population-based studies that reported mortality risks, i.e. relative risks (RRs), odds ratios (ORs) or hazard ratios (HRs) of CVD mortality or cause-specific CVD death. Linear Dose-Response Relationships were assessed using random-effects meta-regression. Potential nonlinear associations were evaluated using restricted cubic splines. Results Out of 3002 articles, 9 articles from 8 independent studies met the eligibility criteria. These studies comprised 449,748 individuals and 10,313 CVD deaths. Compared with the lowest dietary magnesium consumption group in the population, the risk of CVD mortality was reduced by 16% in women and 8% in men. No significant linear Dose-Response Relationship was found between increment in dietary magnesium intake and CVD mortality across all the studies. After adjusting for age and BMI, the risk of CVD mortality was reduced by 24–25% per 100 mg/d increment in dietary magnesium intake in women of all the participants and in all the US participants. Conclusion Although the combined data confirm the role of dietary magnesium intake in reducing CVD mortality, the Dose-Response Relationship was only found among women and in US population.
-
dose response Relationship between dietary magnesium intake and risk of type 2 diabetes mellitus a systematic review and meta regression analysis of prospective cohort studies
Nutrients, 2016Co-Authors: Xin Fang, Hedong Han, Zhongjie Fan, Jan Aaseth, Chun Liang, Scott Montgomery, Yang CaoAbstract:The epidemiological evidence for a Dose-Response Relationship between magnesium intake and risk of type 2 diabetes mellitus (T2D) is sparse. The aim of the study was to summarize the evidence for the association of dietary magnesium intake with risk of T2D and evaluate the Dose-Response Relationship. We conducted a systematic review and meta-analysis of prospective cohort studies that reported dietary magnesium intake and risk of incident T2D. We identified relevant studies by searching major scientific literature databases and grey literature resources from their inception to February 2016. We included cohort studies that provided risk ratios, i.e., relative risks (RRs), odds ratios (ORs) or hazard ratios (HRs), for T2D. Linear Dose-Response Relationships were assessed using random-effects meta-regression. Potential nonlinear associations were evaluated using restricted cubic splines. A total of 25 studies met the eligibility criteria. These studies comprised 637,922 individuals including 26,828 with a T2D diagnosis. Compared with the lowest magnesium consumption group in the population, the risk of T2D was reduced by 17% across all the studies; 19% in women and 16% in men. A statistically significant linear Dose-Response Relationship was found between incremental magnesium intake and T2D risk. After adjusting for age and body mass index, the risk of T2D incidence was reduced by 8%-13% for per 100 mg/day increment in dietary magnesium intake. There was no evidence to support a nonlinear Dose-Response Relationship between dietary magnesium intake and T2D risk. The combined data supports a role for magnesium in reducing risk of T2D, with a statistically significant linear Dose-Response pattern within the reference dose range of dietary intake among Asian and US populations. The evidence from Europe and black people is limited and more prospective studies are needed for the two subgroups.
Michael Flentje - One of the best experts on this subject based on the ideXlab platform.
-
dose response Relationship for radiation induced pneumonitis after pulmonary stereotactic body radiotherapy
Radiotherapy and Oncology, 2010Co-Authors: Matthias Guckenberger, Kurt Baier, Buelent Polat, Anne Richter, Thomas Krieger, Juergen Wilbert, Gerd Mueller, Michael FlentjeAbstract:Abstract Purpose To evaluate dosimetric factors predictive for radiation-induced pneumonitis (RP) after pulmonary stereotactic body radiotherapy (SBRT). Materials and methods A retrospective analysis was performed based on 59 consecutive patients treated with cone-beam CT-based image-guided SBRT for primary NSCLC ( n =21) or pulmonary metastases ( n =54). The majority of patients were treated with radiosurgery of 26Gy to 80% ( n =29) or three fractions of 12.5Gy to 65% ( n =40). To correct for different single fraction doses, local doses were converted to 2Gy equivalent normalized total doses (NTDs) using α/β ratio of 3Gy for RP. Dose–volume parameters and incidences of RP⩾grade II SWOG were fitted using NTCP models. Results Eleven patients developed RP grade II. With an average MLD of 10.3±5.6Gy to the ipsilateral lung, a significant dose–response Relationship was observed: the MLD was 12.5±4.3Gy and 9.9±5.8Gy for patients with and without development of RP, respectively. Additionally, volumes of the lung exposed to minimum doses between 2.5 and 50Gy ( V 2.5 – V 50 ) were correlated with incidences of RP with a continuous decrease of the goodness of fit for higher doses. Conclusions The MLD and V 2.5 – V 50 of the ipsilateral lung were correlated with incidences of RP after pulmonary SBRT.
-
dose response Relationship for image guided stereotactic body radiotherapy of pulmonary tumors relevance of 4d dose calculation
International Journal of Radiation Oncology Biology Physics, 2009Co-Authors: Matthias Guckenberger, Kurt Baier, Anne Richter, Thomas Krieger, Juergen Wilbert, Gerd Mueller, Joern Wulf, Manuela Gabor, Michael FlentjeAbstract:Purpose To evaluate outcome after image-guided stereotactic body radiotherapy (SBRT) for early-stage non–small-cell lung cancer (NSCLC) and pulmonary metastases. Methods and Materials A total of 124 patients with 159 pulmonary lesions (metastases n = 118; NSCLC, n = 41; Stage IA, n = 13; Stage IB, n = 19; T3N0, n = 9) were treated with SBRT. Patients were treated with hypofractionated schemata (one to eight fractions of 6–26 Gy); biologic effective doses (BED) to the clinical target volume (CTV) were calculated based on four-dimensional (4D) dose calculation. The position of the pulmonary target was verified using volume imaging before all treatments. Results With mean/median follow-up of 18/14 months, actuarial local control was 83% at 36 months with no difference between NSCLC and metastases. The dose to the CTV based on 4D dose calculation was closely correlated with local control: local control rates were 89% and 62% at 36 months for >100 Gy and p = 0.0001), respectively. Actuarial freedom from regional and systemic progression was 34% at 36 months for primary NSCLC group; crude rate of regional failure was 15%. Three-year overall survival was 37% for primary NSCLC and 16% for metastases; no dose–response Relationship for survival was observed. Exacerbation of comorbidities was the most frequent cause of death for primary NSCLC. Conclusions Doses of >100 Gy BED to the CTV based on 4D dose calculation resulted in excellent local control rates. This cutoff dose is not specific to the treatment technique and protocol of our study and may serve as a general recommendation.
-
dose response Relationship for image guided stereotactic body radiotherapy of pulmonary tumors relevance of 4d dose calculation
International Journal of Radiation Oncology Biology Physics, 2009Co-Authors: Matthias Guckenberger, Kurt Baier, Anne Richter, Thomas Krieger, Juergen Wilbert, Gerd Mueller, Joern Wulf, Manuela Gabor, Michael FlentjeAbstract:Purpose To evaluate outcome after image-guided stereotactic body radiotherapy (SBRT) for early-stage non–small-cell lung cancer (NSCLC) and pulmonary metastases. Methods and Materials A total of 124 patients with 159 pulmonary lesions (metastases n = 118; NSCLC, n = 41; Stage IA, n = 13; Stage IB, n = 19; T3N0, n = 9) were treated with SBRT. Patients were treated with hypofractionated schemata (one to eight fractions of 6–26 Gy); biologic effective doses (BED) to the clinical target volume (CTV) were calculated based on four-dimensional (4D) dose calculation. The position of the pulmonary target was verified using volume imaging before all treatments. Results With mean/median follow-up of 18/14 months, actuarial local control was 83% at 36 months with no difference between NSCLC and metastases. The dose to the CTV based on 4D dose calculation was closely correlated with local control: local control rates were 89% and 62% at 36 months for >100 Gy and p = 0.0001), respectively. Actuarial freedom from regional and systemic progression was 34% at 36 months for primary NSCLC group; crude rate of regional failure was 15%. Three-year overall survival was 37% for primary NSCLC and 16% for metastases; no dose–response Relationship for survival was observed. Exacerbation of comorbidities was the most frequent cause of death for primary NSCLC. Conclusions Doses of >100 Gy BED to the CTV based on 4D dose calculation resulted in excellent local control rates. This cutoff dose is not specific to the treatment technique and protocol of our study and may serve as a general recommendation.
Matthias Guckenberger - One of the best experts on this subject based on the ideXlab platform.
-
dose response Relationship with clinical outcome for lung stereotactic body radiotherapy sbrt delivered via online image guidance
Radiotherapy and Oncology, 2014Co-Authors: Larry L Kestin, Matthias Guckenberger, I S Grills, J Belderbos, Andrew Hope, Maria Wernerwasik, Janjakob Sonke, Jeanpierre Bissonnette, Y Xiao, D YanAbstract:Abstract Purpose To examine potential dose–response Relationships with various non-small-cell lung cancer (NSCLC) SBRT fractionation regimens delivered with online CT-based image guidance. Methods 505 tumors in 483 patients with clinical stage T1-T2N0 NSCLC were treated with SBRT using on-line cone-beam-CT-based image guidance at 5 institutions (1998–2010). Median maximum tumor dimension was 2.6cm (range 0.9–8.5cm). Dose fractionation prescription was according to each institution's protocol with the most common schedules of 18–20GyX3, 12GyX4, 12GyX5, 12.5GyX3, 7.5GyX8 (median=54Gy, 3 fractions). Median prescription (Rx) BED 10 =132Gy (50.4–180). Median values (Gy) of 3D planned doses for BED 10 were GTV min =164.1, GTV mean =188.4, GTV max =205.9, PTV min =113.9, PTV D99=123.9, PTV mean =164.7, PTV D1=197.3, PTV max =210.7. Mean follow-up=1.6years. Results 26 cases (5%) had local recurrence (LR) for a 2-year rate of 6% and 3-year rate of 9%. All BED 10 GTV&PTV endpoints were associated with LR as continuous variables on univariate analysis ( p mean dose appeared to have the highest correlation with LR with area under ROC curve of 0.69 and 0.65 respectively and optimal cut points of 105 and 125Gy, respectively. 2-year LR was 4% for PTV mean >125 vs 17% for p 10 >105 was 4% vs 15% for p p p =0.02) with 2-year LR=3% for p =0.03). BED 10 ( p =0.01) and elapsed days during RT ( p =0.05) were independent predictors on multivariate analysis as continuous variables. Conclusions There is a substantial dose–response Relationship for local control of NSCLC following image-guided SBRT with optimal PTV mean BED 10 >125Gy. Shorter treatment duration was also associated with better local control in this dataset.
-
dose response Relationship for radiation induced pneumonitis after pulmonary stereotactic body radiotherapy
Radiotherapy and Oncology, 2010Co-Authors: Matthias Guckenberger, Kurt Baier, Buelent Polat, Anne Richter, Thomas Krieger, Juergen Wilbert, Gerd Mueller, Michael FlentjeAbstract:Abstract Purpose To evaluate dosimetric factors predictive for radiation-induced pneumonitis (RP) after pulmonary stereotactic body radiotherapy (SBRT). Materials and methods A retrospective analysis was performed based on 59 consecutive patients treated with cone-beam CT-based image-guided SBRT for primary NSCLC ( n =21) or pulmonary metastases ( n =54). The majority of patients were treated with radiosurgery of 26Gy to 80% ( n =29) or three fractions of 12.5Gy to 65% ( n =40). To correct for different single fraction doses, local doses were converted to 2Gy equivalent normalized total doses (NTDs) using α/β ratio of 3Gy for RP. Dose–volume parameters and incidences of RP⩾grade II SWOG were fitted using NTCP models. Results Eleven patients developed RP grade II. With an average MLD of 10.3±5.6Gy to the ipsilateral lung, a significant dose–response Relationship was observed: the MLD was 12.5±4.3Gy and 9.9±5.8Gy for patients with and without development of RP, respectively. Additionally, volumes of the lung exposed to minimum doses between 2.5 and 50Gy ( V 2.5 – V 50 ) were correlated with incidences of RP with a continuous decrease of the goodness of fit for higher doses. Conclusions The MLD and V 2.5 – V 50 of the ipsilateral lung were correlated with incidences of RP after pulmonary SBRT.
-
dose response Relationship for image guided stereotactic body radiotherapy of pulmonary tumors relevance of 4d dose calculation
International Journal of Radiation Oncology Biology Physics, 2009Co-Authors: Matthias Guckenberger, Kurt Baier, Anne Richter, Thomas Krieger, Juergen Wilbert, Gerd Mueller, Joern Wulf, Manuela Gabor, Michael FlentjeAbstract:Purpose To evaluate outcome after image-guided stereotactic body radiotherapy (SBRT) for early-stage non–small-cell lung cancer (NSCLC) and pulmonary metastases. Methods and Materials A total of 124 patients with 159 pulmonary lesions (metastases n = 118; NSCLC, n = 41; Stage IA, n = 13; Stage IB, n = 19; T3N0, n = 9) were treated with SBRT. Patients were treated with hypofractionated schemata (one to eight fractions of 6–26 Gy); biologic effective doses (BED) to the clinical target volume (CTV) were calculated based on four-dimensional (4D) dose calculation. The position of the pulmonary target was verified using volume imaging before all treatments. Results With mean/median follow-up of 18/14 months, actuarial local control was 83% at 36 months with no difference between NSCLC and metastases. The dose to the CTV based on 4D dose calculation was closely correlated with local control: local control rates were 89% and 62% at 36 months for >100 Gy and p = 0.0001), respectively. Actuarial freedom from regional and systemic progression was 34% at 36 months for primary NSCLC group; crude rate of regional failure was 15%. Three-year overall survival was 37% for primary NSCLC and 16% for metastases; no dose–response Relationship for survival was observed. Exacerbation of comorbidities was the most frequent cause of death for primary NSCLC. Conclusions Doses of >100 Gy BED to the CTV based on 4D dose calculation resulted in excellent local control rates. This cutoff dose is not specific to the treatment technique and protocol of our study and may serve as a general recommendation.
-
dose response Relationship for image guided stereotactic body radiotherapy of pulmonary tumors relevance of 4d dose calculation
International Journal of Radiation Oncology Biology Physics, 2009Co-Authors: Matthias Guckenberger, Kurt Baier, Anne Richter, Thomas Krieger, Juergen Wilbert, Gerd Mueller, Joern Wulf, Manuela Gabor, Michael FlentjeAbstract:Purpose To evaluate outcome after image-guided stereotactic body radiotherapy (SBRT) for early-stage non–small-cell lung cancer (NSCLC) and pulmonary metastases. Methods and Materials A total of 124 patients with 159 pulmonary lesions (metastases n = 118; NSCLC, n = 41; Stage IA, n = 13; Stage IB, n = 19; T3N0, n = 9) were treated with SBRT. Patients were treated with hypofractionated schemata (one to eight fractions of 6–26 Gy); biologic effective doses (BED) to the clinical target volume (CTV) were calculated based on four-dimensional (4D) dose calculation. The position of the pulmonary target was verified using volume imaging before all treatments. Results With mean/median follow-up of 18/14 months, actuarial local control was 83% at 36 months with no difference between NSCLC and metastases. The dose to the CTV based on 4D dose calculation was closely correlated with local control: local control rates were 89% and 62% at 36 months for >100 Gy and p = 0.0001), respectively. Actuarial freedom from regional and systemic progression was 34% at 36 months for primary NSCLC group; crude rate of regional failure was 15%. Three-year overall survival was 37% for primary NSCLC and 16% for metastases; no dose–response Relationship for survival was observed. Exacerbation of comorbidities was the most frequent cause of death for primary NSCLC. Conclusions Doses of >100 Gy BED to the CTV based on 4D dose calculation resulted in excellent local control rates. This cutoff dose is not specific to the treatment technique and protocol of our study and may serve as a general recommendation.
Xin Fang - One of the best experts on this subject based on the ideXlab platform.
-
dose response Relationship between dietary magnesium intake and cardiovascular mortality a systematic review and dose based meta regression analysis of prospective studies
Journal of Trace Elements in Medicine and Biology, 2016Co-Authors: Xin Fang, Jan Aaseth, Chun Liang, Scott Montgomery, Yang Cao, Katja FallAbstract:Abstract Background Although epidemiology studies have reported the Relationship, including a Dose-Response Relationship, between dietary magnesium intake and risk of cardiovascular disease (CVD), the risk for CVD mortality is inconclusive and the evidence for a Dose-Response Relationship has not been summarized. Objective We conducted a systematic review and meta-analysis of prospective studies to summarize the evidence regarding the association of dietary magnesium intake with risk of CVD mortality and describe their Dose-Response Relationship. Design We identified relevant studies by searching major scientific literature databases and grey literature resources from their inception to August 2015, and reviewed references lists of retrieved articles. We included population-based studies that reported mortality risks, i.e. relative risks (RRs), odds ratios (ORs) or hazard ratios (HRs) of CVD mortality or cause-specific CVD death. Linear Dose-Response Relationships were assessed using random-effects meta-regression. Potential nonlinear associations were evaluated using restricted cubic splines. Results Out of 3002 articles, 9 articles from 8 independent studies met the eligibility criteria. These studies comprised 449,748 individuals and 10,313 CVD deaths. Compared with the lowest dietary magnesium consumption group in the population, the risk of CVD mortality was reduced by 16% in women and 8% in men. No significant linear Dose-Response Relationship was found between increment in dietary magnesium intake and CVD mortality across all the studies. After adjusting for age and BMI, the risk of CVD mortality was reduced by 24–25% per 100 mg/d increment in dietary magnesium intake in women of all the participants and in all the US participants. Conclusion Although the combined data confirm the role of dietary magnesium intake in reducing CVD mortality, the Dose-Response Relationship was only found among women and in US population.
-
dose response Relationship between dietary magnesium intake and risk of type 2 diabetes mellitus a systematic review and meta regression analysis of prospective cohort studies
Nutrients, 2016Co-Authors: Xin Fang, Hedong Han, Zhongjie Fan, Jan Aaseth, Chun Liang, Scott Montgomery, Yang CaoAbstract:The epidemiological evidence for a Dose-Response Relationship between magnesium intake and risk of type 2 diabetes mellitus (T2D) is sparse. The aim of the study was to summarize the evidence for the association of dietary magnesium intake with risk of T2D and evaluate the Dose-Response Relationship. We conducted a systematic review and meta-analysis of prospective cohort studies that reported dietary magnesium intake and risk of incident T2D. We identified relevant studies by searching major scientific literature databases and grey literature resources from their inception to February 2016. We included cohort studies that provided risk ratios, i.e., relative risks (RRs), odds ratios (ORs) or hazard ratios (HRs), for T2D. Linear Dose-Response Relationships were assessed using random-effects meta-regression. Potential nonlinear associations were evaluated using restricted cubic splines. A total of 25 studies met the eligibility criteria. These studies comprised 637,922 individuals including 26,828 with a T2D diagnosis. Compared with the lowest magnesium consumption group in the population, the risk of T2D was reduced by 17% across all the studies; 19% in women and 16% in men. A statistically significant linear Dose-Response Relationship was found between incremental magnesium intake and T2D risk. After adjusting for age and body mass index, the risk of T2D incidence was reduced by 8%-13% for per 100 mg/day increment in dietary magnesium intake. There was no evidence to support a nonlinear Dose-Response Relationship between dietary magnesium intake and T2D risk. The combined data supports a role for magnesium in reducing risk of T2D, with a statistically significant linear Dose-Response pattern within the reference dose range of dietary intake among Asian and US populations. The evidence from Europe and black people is limited and more prospective studies are needed for the two subgroups.
Michael S Hofman - One of the best experts on this subject based on the ideXlab platform.
-
impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma establishing a dose response Relationship
Radiotherapy and Oncology, 2016Co-Authors: Shankar Siva, Price Jackson, Tomas Kron, Mathias Bressel, Eddie Lau, Michael S HofmanAbstract:Abstract Background and purpose To evaluate renal dysfunction after stereotactic ablative body radiotherapy (SABR) for inoperable primary renal cell carcinoma (RCC) using nuclear medicine assessments. Materials and methods In a prospective clinical trial, patients received single fraction renal SABR (26Gy) for tumours 51 Cr-EDTA and 99m Tc-DMSA SPECT/CT, respectively, at baseline and post-treatment (14, 90days and at 1-year). Regional loss in function was correlated to the absolute and biologically effective doses (BED) delivered. Results In 21 patients the mean (range) tumour size was 48mm (21–75mm). The mean±SD GFR at baseline was 52±24ml/min. Net change in mean GFR was +0.6±11.3, +3.2±14.5 and −8.7±13.4 ml/min ( p =0.03) at 2weeks, 3months and 1year, respectively. For every 10Gy of physical dose delivered, an exponential decline in affected kidney GFR was observed at 39% for 26Gy/1 fraction and 25% for 42Gy/3 fractions. When normalised to BED 3Gy , the dose–response Relationship for each treatment prescription was similar with a plateau beyond 100Gy. The R50% conformity index correlated with GFR loss ( p =0.04). No patient required dialysis. Conclusions SABR results in clinically acceptable and dose-dependent renal dysfunction at 1-year. Sparing functional kidney from high-dose regions (>50% isodoses) may help reduce risk of functional loss.